Reposted by LessBarb
“We’re at a period where our molecular understanding is unprecedented,” said Dr. Paul Mischel, a physician scientist at Stanford. “But the infrastructure is really falling apart.”
“It’s a problem — it’s a big, big problem,” he added. “People should be really angry.”
nytimes.com
New Cancer Drugs Are Revolutionary. Why Don’t More Patients Get Them?
Targeted gene therapies are highly effective at stopping cancers, but the very abundance of the treatments, plus cost and sluggish change, are hindering access.
